4.62
-0.03(-0.65%)
Currency In USD
| Previous Close | 4.65 |
| Open | 4.64 |
| Day High | 4.64 |
| Day Low | 4.55 |
| 52-Week High | 4.8 |
| 52-Week Low | 2.46 |
| Volume | 231,275 |
| Average Volume | 444,156 |
| Market Cap | 360.95M |
| PE | -2.61 |
| EPS | -1.77 |
| Moving Average 50 Days | 3.73 |
| Moving Average 200 Days | 3.36 |
| Change | -0.03 |
If you invested $1000 in Atea Pharmaceuticals, Inc. (AVIR) since IPO date, it would be worth $152.27 as of February 25, 2026 at a share price of $4.62. Whereas If you bought $1000 worth of Atea Pharmaceuticals, Inc. (AVIR) shares 5 years ago, it would be worth $56.83 as of February 25, 2026 at a share price of $4.62.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
GlobeNewswire Inc.
Yesterday at 12:00 PM GMT
Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus Initiation of Phase 1 Clinical Program Anticipated Mid-2026 BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 08, 2026 12:00 PM GMT
Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026 Topline Results from North American Phase 3 C-BEYOND Trial Expected Mid-2026; Results from C-FORWARD Trial Outside North America Expected Year-End 2026
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2026 12:00 PM GMT
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, to